GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinotherapeutics Inc (SHSE:688247) » Definitions » Net Income Including Noncontrolling Interests

Sinotherapeutics (SHSE:688247) Net Income Including Noncontrolling Interests : ¥76.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sinotherapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Sinotherapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was ¥22.9 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was ¥76.3 Mil.

Sinotherapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Sinotherapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinotherapeutics Net Income Including Noncontrolling Interests Chart

Sinotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial 4.64 123.30 134.92 92.93 61.07

Sinotherapeutics Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.72 15.06 21.29 17.00 22.90

Sinotherapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥76.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinotherapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Sinotherapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinotherapeutics (SHSE:688247) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinotherapeutics Inc (SHSE:688247) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
SHSE:603520 SZSE:300485 SZSE:300110 SZSE:002644 SHSE:688566 SHSE:688073 SZSE:300194 SHSE:600488 SZSE:002393 SZSE:002728 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
No. 515 Huanke Road, Room 205 and 207, Pilot Free Trade Zone, Shanghai, CHN, 201203
Website
http://www.sinotherapeutics.com
Sinotherapeutics Inc is engaged in the research and development, production and sales of generic drugs and CRO services.

Sinotherapeutics (SHSE:688247) Headlines

No Headlines